Compare Ferrari NV (RACE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Tango Therapeutics Inc. — how do they compare? Ferrari NV trades at $392.6 (market cap $68.73B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Ferrari NV is far larger — about 18.3× Tango Therapeutics Inc.'s market cap, and Ferrari NV pays a 1.08% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Tango Therapeutics Inc. for 0 Days on average.
| RACE | TNGX | |
|---|---|---|
Market Cap | $68.73B | $3.75B |
Volume | 283,474 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $32.90 |
52-Week Low | $314.63 | $7.50 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $70.60B | $2.77B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $387.35, down 0.49% on the day, amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $7.15B in 2025 to a projected $7.4B in 2026 and a net income margin of 22.25%. Recent earnings beats and a share buyback program highlight operational strength. Analyst consensus is bullish with a $462.75 price target, though technical indicators show near-term pressure with support at $384.
The outlook remains positive given Ferrari's premium brand and consistent profitability, but high valuation multiples (P/E 37.67) and economic sensitivity pose risks. Institutional buying and bullish analyst ratings support upside potential, yet investors should monitor competitive pressures and macroeconomic headwinds that could impact luxury demand.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
